Randomized Trialhigh evidence
Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial.
Lancet (London, England)·December 20, 2026·PMID 41275879
Why it mattersThis is the first randomized evidence directly comparing PAXG to mFOLFIRINOX in the preoperative setting for pancreatic cancer, showing a meaningful EFS benefit that may influence chemotherapy selection.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled